CA9 and skin cancer: Compound 4f, as one of the most potent inhibitors of CA IX and XII, exhibits hypoxic selectivity, suppressing the growth of MCF7 cells at 12.9 μM, and causes partial inhibition of hypoxia-induced CA IX expression in A431 skin cancer cells.